Veru Inc.
verupharma.comWhat Do They Do?
Develops enobosarm for people with obesity taking weight-loss drugs and sabizabulin for people with atherosclerotic cardiovascular disease.
10-K for FY2025, filed Dec 17, 2025We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and…View ↗
Our metabolic drug pipeline is focused on the clinical development of enobosarm, an oral SARM, as a treatment to preserve muscle and…View ↗
Veru has evolved its drug development strategy for sabizabulin and is exploring the possibility of the clinical development of sabizabulin…View ↗
How Do They Make Money?
-
10-K for FY2024, filed Dec 16, 2024
FY2024 revenue by product or service ↗
$16.9M
-
10-K for FY2024, filed Dec 16, 2024
$16.9M ↗
| Segment | Share | Revenue |
|---|---|---|
|
FC2 Female Condom
|
100% |
FC2 Female Condom, FY2024
$16.9M Sources
|
|
Product and Service, Other
|
0.0% |
Product and Service, Other, FY2024
$0 Sources
|
Do Revenues Turn Into Profits?
No. It lost $37.8M in FY2024.
10-K for FY2025, filed Dec 17, 2025
−$36.2MView ↗
10-K for FY2025, filed Dec 17, 2025
−$37.8MView ↗
10-K for FY2025, filed Dec 17, 2025
−$21.9MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Aug 10, 2026
−$7MView ↗
- ▼ −5% (Loss)
- vs −$7.3M in Q3 FY2025
-
Sep 8, 2026
Veru redirects sabizabulin toward drug-resistant pancreatic cancer
It plans a Phase 2 trial for metastatic pancreatic cancer resistant to daraxonrasib and will stop pursuing cardiovascular inflammation.
Sources
8-K, filed Sep 8, 2026
Based on the new, positive preclinical data, and the previous preclinical and clinical sabizabulin studies, the Company will advance…View ↗
Shrinking. Revenue fell 60% in 4 years, from $42.6M in FY2020 to $16.9M in FY2024, about 21% a year.
Therapeutic focus
The older report covered COVID-related illness, breast and prostate cancers, and sexual health; the latest focuses on obesity and cardiovascular and inflammatory diseases.
10-K for FY2022, filed Dec 5, 2022 10-K for FY2025, filed Dec 17, 2025We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and…View ↗
Our strategy focuses primarily on the clinical development and commercialization of novel medicines for the treatment of metabolic…View ↗
Our metabolic drug pipeline is focused on the clinical development of enobosarm, an oral SARM, as a treatment to preserve muscle and…View ↗
Veru has evolved its drug development strategy for sabizabulin and is exploring the possibility of the clinical development of sabizabulin…View ↗
Commercial product sale
The older report listed the female condom among approved products and aimed to grow sexual health; the latest says it sold that business and focuses on drug development.
10-K for FY2022, filed Dec 5, 2022 10-K for FY2025, filed Dec 17, 2025Veru is a biopharmaceutical company with a drug development program for the treatment of hospitalized COVID-19 patients at high risk for…View ↗
Our StrategyView ↗
oWe are working toward the goal of returning to revenue growth from FC2 in the U.S. market through prescription sales via our established…View ↗
Loading...
